Enzyme Activity in Relation to Cancer: Inhibition of Urinary Beta-Glucuronidase of Patients with Cancer of the Bladder by Oral Administration of 1:4-Saccharolactone and Related Compounds
1957

Inhibition of Urinary Beta-Glucuronidase in Bladder Cancer Patients

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): E. Boyland, D. M. Wallace, D. C. Williams

Primary Institution: Chester Beatty Research Institute, Institute of Cancer Research: Royal Cancer Hospital, London

Hypothesis

If the urinary beta-glucuronidase activity in patients, in which new tumours would be expected to develop, could be inhibited, then these tumours should be prevented.

Conclusion

Oral administration of 1 g. saccharo-1:4-lactone every 6 hours decreases the enzyme activity in the urine by 90 percent.

Supporting Evidence

  • Urinary beta-glucuronidase activity is almost always increased in the urine of patients with cancer of the bladder.
  • Treatment with saccharo-1:4-lactone reduced the urinary beta-glucuronidase activity by 90 percent.
  • Patients treated with sodium ammonium saccharate showed a 31 percent reduction in enzyme activity.

Takeaway

This study found that a special sugar compound can help lower harmful substances in the urine of bladder cancer patients, which might help prevent new tumors.

Methodology

Patients were treated with various inhibitors to decrease urinary beta-glucuronidase activity, and urine samples were collected to measure enzyme levels.

Limitations

The treatment has not been used long enough to draw definitive conclusions about clinical benefits.

Participant Demographics

Patients suffering from bladder cancer with a history of more than 2 years.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication